Distinguishing among incretin-based therapies. Pathophysiology of type 2 diabetes mellitus: potential role of incretin-based therapies. [electronic resource]
Producer: 20101207Description: S5-9 p. digitalISSN:- 1533-7294
- Adamantane -- analogs & derivatives
- Aged
- Blood Glucose
- Diabetes Mellitus, Type 2 -- drug therapy
- Dipeptides -- therapeutic use
- Exenatide
- Female
- Glucagon -- metabolism
- Glucagon-Like Peptide 1 -- analogs & derivatives
- Humans
- Hypoglycemic Agents -- therapeutic use
- Incretins -- therapeutic use
- Insulin-Secreting Cells -- physiology
- Liraglutide
- Male
- Metformin -- therapeutic use
- Middle Aged
- Peptides -- therapeutic use
- Pyrazines -- therapeutic use
- Severity of Illness Index
- Sitagliptin Phosphate
- Time Factors
- Triazoles -- therapeutic use
- Venoms -- therapeutic use
No physical items for this record
Publication Type: Case Reports; Journal Article
There are no comments on this title.
Log in to your account to post a comment.